Precigen Inc

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

Precigen Reports Full Year 2025 Financial Results and Business Updates

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference